Nu-Med Plus (NUMD) Net Cash Flow Growth (3y) (2015 - 2025)
Nu-Med Plus (NUMD) Net Cash Flow Growth (3y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.71 Bn | 194.11 Bn | 7.27 Bn | -9.45% |
| 2 | Stryker | 129.50 Bn | 126.03 Bn | 4.50 Bn | 60.16% |
| 3 | Medtronic | 119.85 Bn | 110.63 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 73.79 Bn | 73.25 Bn | 3.85 Bn | -85.83% |
| 5 | Edwards Lifesciences | 52.68 Bn | 48.42 Bn | 1.35 Bn | 43.26% |
| 6 | Dexcom | 34.58 Bn | 32.64 Bn | 830.00 Mn | -26.30% |
| 7 | GE HealthCare Technologies | 34.14 Bn | 32.03 Bn | 2.18 Bn | 21.48% |
| 8 | Koninklijke Philips | 26.45 Bn | 23.13 Bn | 4.55 Bn | -127.77% |
| 9 | Steris | 23.23 Bn | 22.74 Bn | 684.20 Mn | 269.22% |
| 10 | Nu-Med Plus | 1.70 Mn | 1.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 62.51% |
| Sep 30, 2025 | -172.24% |
| Dec 31, 2024 | 56.43% |
| Jun 30, 2024 | 67.34% |
| Mar 31, 2024 | 79.09% |
| Dec 31, 2023 | -26.56% |
| Sep 30, 2023 | -39.98% |
| Jun 30, 2023 | -23.59% |
| Mar 31, 2023 | -55.95% |
| Dec 31, 2022 | 11.09% |
| Sep 30, 2022 | -71.15% |
| Jun 30, 2022 | 30.60% |
| Mar 31, 2022 | 60.14% |
| Dec 31, 2021 | -199.71% |
| Sep 30, 2021 | 30.12% |
| Jun 30, 2021 | -92.37% |
| Mar 31, 2021 | 13.33% |
| Dec 31, 2020 | 67.44% |
| Sep 30, 2020 | -44.15% |
| Jun 30, 2020 | 39.06% |